Loading…
BioCryst Pharmaceuticals, Inc. is projected to rise to $11.00 by 2027, a +19% move from its current price of $9.24. BCRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $9.02 | $9.24 | $9.47 | +0.01% |
| Aug 2 | $8.93 | $9.24 | $9.57 | +0.03% |
| Aug 3 | $8.86 | $9.24 | $9.64 | +0.04% |
| Aug 4 | $8.81 | $9.25 | $9.71 | +0.06% |
| Aug 5 | $8.76 | $9.25 | $9.77 | +0.07% |
| Aug 6 | $8.71 | $9.25 | $9.82 | +0.09% |
| Aug 7 | $8.67 | $9.25 | $9.87 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.67 | $9.25 | $9.87 | +0.10% |
| Week 2 | $8.45 | $9.26 | $10.14 | +0.21% |
| Week 3 | $8.29 | $9.27 | $10.36 | +0.31% |
| Week 4 | $8.15 | $9.28 | $10.56 | +0.41% |
| Week 5 | $8.04 | $9.29 | $10.73 | +0.52% |
| Week 6 | $7.94 | $9.30 | $10.89 | +0.62% |
| Week 7 | $7.85 | $9.31 | $11.04 | +0.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.
BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc. trades under the symbol BCRX and currently sits with a price of $9.41 and a market cap of $2.39B, ranking 1924 by market size.
The stock’s near-term technical backdrop is bullish, with a sentiment read as BULLISH and RSI14 at 50. The 50-day simple moving average sits at $9.18 and the 200-day simple moving average at $8.11, placing current action above both averages.
The 30-day range spans $7.78 to $11.39, with a support level at $8.19 and a resistance at $11.11. These dynamics frame a near-term path that could push toward the upper end of the interval if momentum persists. The longer-term forecast envisions a rising trajectory, anchored by a 2026 average of $9.41 and extending to $14.95 by 2030 and $73.88 by 2050, with a max of $139.57 in 2050.
A major floor 17.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.1% below — buyers have tended to step in here.
The nearest ceiling, 20.2% above — a clean break opens room to run.
A major ceiling 29.1% above — clearing it would confirm fresh momentum.
Key BCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.49 | Sell | $9.44 | Sell |
| MA 10 | $9.41 | Sell | $9.50 | Sell |
| MA 20 | $9.78 | Sell | $9.55 | Sell |
| MA 50 | $9.26 | Sell | $9.39 | Sell |
| MA 100 | $9.22 | Buy | $9.07 | Buy |
| MA 200 | $8.22 | Buy | $8.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.31 | Neutral |
| Stoch RSI (14) | 22.82 | Neutral |
| CCI (20) | -75.98 | Neutral |
| Williams %R (14) | -83.75 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -5.13 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 16.25 | Buy |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 40.35 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 9.57 | Sell |
| ADX (14) | 11.91 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish overall, supported by a positive sentiment reading and price action trading near key moving averages.
RSI 14 sits at 50, with the SMA50 at $9.18 and the SMA200 at $8.11, suggesting the price is near an average reference zone and could move with renewed momentum.
The near-term range runs from a low of $7.78 to a high of $11.39 over the last 30 days, with support at $8.19 and resistance at $11.11, defining a clear zone where buyers and sellers have previously clashed.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.24 | $9.24 | $11.85 | 0% | Neutral | |
| $8.86 | $11.00 | $14.39 | +19% | Neutral | |
| $9.08 | $11.56 | $15.64 | +25% | Bullish | |
| $9.65 | $12.54 | $17.42 | +36% | Bullish | |
| $10.27 | $13.59 | $19.31 | +47% | Bullish | |
| $10.58 | $14.24 | $20.63 | +54% | Bullish | |
| $12.55 | $17.14 | $25.28 | +85% | Bullish | |
| $14.58 | $20.21 | $30.28 | +119% | Bullish | |
| $15.49 | $21.75 | $33.08 | +135% | Bullish | |
| $15.77 | $22.42 | $34.57 | +143% | Bullish | |
| $23.57 | $35.52 | $57.98 | +284% | Bullish | |
| $35.88 | $59.67 | $105.87 | +546% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.24 | $9.24 | $10.77 | +0.00% |
| August 2026 | $7.88 | $9.23 | $11.05 | -0.08% |
| September 2026 | $7.94 | $9.37 | $11.34 | +1.44% |
| October 2026 | $8.18 | $9.71 | $11.87 | +3.70% |
| November 2026 | $8.17 | $9.74 | $12.00 | +0.30% |
| December 2026 | $7.97 | $9.55 | $11.85 | -1.95% |
Click any year to see its month-by-month BCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BCRX could reach as high as $11.85, with a base case around $9.24 and support toward $6.24 — roughly 0% from $9.24. Price action looks broadly range-bound.
Expect BCRX to range from $8.86 to $14.39 through 2027. The $11.00 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
The BCRX price prediction for 2028 points to an average of $11.56 (low $9.08, high $15.64) — a potential gain of +25% on today's $9.24. Momentum favours further upside here.
In 2029, BCRX is projected to trade between $9.65 and $17.42, averaging $12.54 — a potential gain of +36% from today's $9.24. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
BioCryst Pharmaceuticals, Inc.'s 2030 outlook centres on $13.59, within a $10.27 to $19.31 range. That is up +8% on the projected 2029 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2031, BCRX could reach as high as $20.63, with a base case around $14.24 and support toward $10.58 — roughly +54% from $9.24. Buyers look set to stay in control over this stretch.
Expect BCRX to range from $12.55 to $25.28 through 2032. The $17.14 average target implies a +85% move from current prices. That is up +20% on the projected 2031 average. Momentum favours further upside here.
The BCRX price prediction for 2033 points to an average of $20.21 (low $14.58, high $30.28) — a potential gain of +119% on today's $9.24. Buyers look set to stay in control over this stretch.
In 2034, BCRX is projected to trade between $15.49 and $33.08, averaging $21.75 — a potential gain of +135% from today's $9.24. That is up +8% on the projected 2033 average. Momentum favours further upside here.
BioCryst Pharmaceuticals, Inc.'s 2035 outlook centres on $22.42, within a $15.77 to $34.57 range. That is up +3% on the projected 2034 average. That marks a +143% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BCRX could reach as high as $57.98, with a base case around $35.52 and support toward $23.57 — roughly +284% from $9.24. Momentum favours further upside here.
Expect BCRX to range from $35.88 to $105.87 through 2050. The $59.67 average target implies a +546% move from current prices. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCRX today (≈ 108.225108 BCRX) could be worth
$6,457.86
+$5,457.86 (+546%) by 2050 · US Dollar
Based on the average projected BCRX price of $59.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCRXwould be worth at today's price.
$1,000 invested in BCRX on Jul 30, 2025 (≈ 121.654497 BCRX) would be worth
$1,124.09
+$124.09 (+12.4%) today · 1.12× · US Dollar
Based on a BCRX entry price of $8.22 vs. today's $9.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.38 | $985.07 | -1.5% |
| 1 month ago | $10 | $924 | -7.6% |
| 3 months ago | $9.19 | $1,005.44 | +0.5% |
| 6 months ago | $6.58 | $1,404.26 | +40.4% |
| 1 year ago | $8.22 | $1,124.09 | +12.4% |
| All time (5.0y) ago | $16.1 | $573.91 | -42.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCRX forecast.
Our base-case forecast reaches $18.00 around 2033.
Implied market cap at $18.00: $4.57B
The multi-year forecast shows sustained upside from 2026 through 2050, with an upward trajectory in average prices across the horizon.
In 2026 the average is forecast at $9.41, rising to $14.95 by 2030 and climbing further to $73.88 by 2050, with a max of $139.57 in 2050.
Projected ROI strengthens over time, starting at 0% in 2026 and rising to 23.7% in 2027, 28.7% in 2028, 42.8% in 2029, 58.9% in 2030, 64.5% in 2031, 111.8% in 2032, 155% in 2033, 164.7% in 2034, 179.2% in 2035, 363.4% in 2040, and 685.1% in 2050, with a bullish sentiment attached to each step.
Overall, the forecast depicts meaningful upside potential across the long horizon, though these are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $14.95, a min of $10.97, and a max of $22.00, with a ROI of 58.9% and bullish sentiment.
The forecast is bullish from 2027 onward, with 2027 avg $11.64 (23.7% ROI), 2028 avg $12.11 (28.7% ROI), 2029 avg $13.44 (42.8% ROI), and higher through 2050, reflecting rising averages and upside potential.
The 2040 forecast shows a max of $75.03, implying the possibility of topping $50 within the forecast window.
Current price is $9.41. The 30-day range is $7.78 to $11.39, with support at $8.19 and resistance at $11.11.
The avg price rises from $9.41 in 2026 to $73.88 in 2050, with a 2050 max of $139.57 and cumulative ROI up to 685.1%; notable milestones include 2027 avg $11.64 (23.7% ROI), 2030 avg $14.95 (58.9% ROI), 2040 avg $43.61 (363.4% ROI).
BioCryst Pharmaceuticals, Inc. Community Discussion
0Share your BioCryst Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.